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Methods: Eight P. aeruginosa isolates were obtained from clinical samples.
PMNs were freshly isolated from healthy human blood. Respiratory burst
was assessed by measurement ofluminol-enhanced chemiluminescence, and
the bactericidal activity of the PMNs was monitored via the loss ofbaeterial
viability (counting of colony-forming units). The bacteria were pre-treated
with ciprofloxacin at 0.5, 1.0 and 5.0 times MIC.
Results: The pre-treatment had no effect on bactericidal activity: nor on the
number of killed bacteria (5 x 102-2 x 103), neither on the time of action
(within I h, P > 0.1). After pre-treatment the respiratory burst started earlier
than in the untreated control (20 versus more than 90 min.). The respiratory
burst maximums are in between 1.5-7.0 mV and the response times are 10-
30 min.
Conclusions: The effects ofciprofloxacin on the bactericidal aL'tivity and the
respiratory burst differed and exhibited no clear connection with the
resistance (MIC) of isolates.
P:5/10 - Quinupristin/Dalfopristin
[WeP136] In vitro activity of qulnupristln/dalfopristin
(synercid) against gram-positive cocci Isolated from severe
infections in Poland
]. Krzyszton-Russjan. K. Nowak, W. Hryniewicz
Sera & Vaccines Central Research Laboratory, Warsaw, Poland
Objectives: To evaluate susceptibility to quinupristin/dalfopristin (Q-D) of
clinical isolates of major Gram-positive pathogens.
Methods: Two hundred and eighty-two clinical isolates of various Gram-
positive bacteria were used in the study. The collection consisted ofstrains of
Streptococcus pneumoniae (n = 40), S. pyogene.s (n = 10). Enterococcusfaecium
(n = 60), Staphylococcus aureus (MRSA, n = 40; MSSA, n = 60) and
coagulase-negative staphylococci. CNS (MRCNS, n = 42; MSCNS, n =
30). Susceptibility testing ofstreptococci was performed with E-tests, and of
staphylococci and enterococci - by disc-dilfusion method according to
NCClS. Strains observed as resistant to Q-D were additionally charac-
terised by MIC evaluation using E-tests and the agar dilution method in
accordance with the NCClS guidelines.
Results: All isolates of S. pneumoniae, S. pyogenes, and Staphylococcus spp.
were found susceptible to Q-D. Out of E. faecium strains two isolates
demonstrated resistance to this antibiotic. These isolates were characterised
by MIC values of4-8 Itg/m!. MICs ofQ-D for S. pneumoniae strains were
evaluated as 0.5-1.0 1Jg/ml, and for S. pyogenes strains - as 0.25-0.38Itg/m!.
Condusions: The study revealed a very high in vitro activity ofquinupristin/
dalfopristin against major Gram-positive pathogens. The antibiutic may be
very useful in treatment ofserious infections caused by multiresistant strains
(e.g. MRSA and vancomycin-resistant E.faecium).
IWeP137!ln vitro activities of quinupristin-dalfopristin.
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P. R. Hsueh!, L.]. Teng l ,].]. lu2,].]. WuJ , H.]. Pan l • Y. C. Chen!, S.
W. HOI, K. T. luh!
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Objectives: To determine the in vitro activities ofquinupristin-dalfopristin,
linezolid, and new quinolones for recent clinical isolates of gram-positive
bacteria.
Methods: A total of 1210 nonduplicate. clinical isolates of gram-positive
bacteria were recovered patients mainly treated at National Taiwan Uni-
versity Hospital (NTUH) from January 1996 to December 1999. These
isolates included 100 blood isolates of methicillin-resistant Staphylococcus
aureus, 461 ofcoagulasenegative staphylococci, 267 ofS. pneumoniae, 120 of
viridans streptococci, 150 ofVRE (vancomycin MICs of ~321Jg/ml).35 of
Leuconostocspp_spp., 8 ofPediococcus spp., and 69 ofLactobacillus spp. MICs of
these isolates for 12 antimicrobial agents were determined by using the
standard methods recommended by the National Committee for Clinical
Laboratory standards (NCelS).
Results: linezolid demonstrated the most potent activity (MIC90s, 2 1Jg/
ml) against all isolates tested. including MRSA. VRE, and vancomycin-
resistant bacteria. Quinupristin-dalfopristin showed limited activity against
vancvomycin-resistant E.faetium (MIC90, 16 pg/mL), Pediococcus (MIC90.
128 JIg/ml.), LeuconoSlOC (MIC90. 128 JIg/mL). and Lactobacillus spp.
(MIC90, 16 1Jg/ml). Moxifloxacin and trovafloxacin had good activity
against these isolates except for ciprofloxacin-resistant VRE and methicilIin-
resistant staphylococci.
Conduslons: Linezolid appears to be a promising antimicrobial agent for
the treatment of infections caused by gram-positive bacteria. Quinupristin-
dalfopristin is not a suitable alternative for managing infections due to
vancomycin-resistant E.faecium in Taiwan.
[WeP~ Antimicrobial combinations against MRSA .
S. Cassey. P. R. Chadwick
Salford Royal Hospitals NHS Trust, Salford, United Kingdom
Objective: To study the antibacterial effect of combinations of teicoplanin
en and quinupristin/dalfopristin (Q/D) with broad-spectrum antimicrobial
agents against MRSA (methicillin-resistant Staphylococcus aureus).
Methods: 10 diverse clinical isolates of MRSA were studied. MICs were
determined by Etest. Time-kill studies were performed using a broth
macrodilution method. Combinations oft and Q/D were studied with
ceftazidime, cefepime, piperaciIlin-tazobactam and meropcnem.
Results: T and Q/D alone had cidal and static activity respectively against
the isolates tested. Antagonism was demonstrated between T and Q/D for9{
10 isolates. Synergic or antagonistic effects were not generally seen with
combinations ofeither T or Q/D and broad-spectrum antimicrobial agents.
Conclusions: This srudy did not suggest any potential benefit or contra-
indication to the concurrent use of selected broad-spectrum antimicrobials
duting treatment ofMRSA infection with either T or Q/D. A potential for
antagonism between T and Q/D was demonstrated.
P:5/11 - Rifampicin
[WeP13SI Relationship between rpoB mutations in
Staphylococcus aureus and antimicrobial activities of rifampicin
and KRM-1648
T. A. Wichelhaus. V. Schafer, V. Brade. B. Boddinghaus
Institute ofMedical Microbiology, Frankfurt am Main, Germany
Objectives: This study was aimed at determining the in vitro antibacterial
activities of the rifamycin derivatives rifampicin and KRM-I648 against
Staphylococcus aureus and at correlating the level of resistance to both
rifamycins with the genetic alterations in the rpoB gene.
Methods: The in vitro antibacterial activities were determined against 150
Seaphylocouus aurt:'us isolates, induding 50 rifampicin_sensitive (R..ir) methi_
cillin-sensitive Staphylococcus aureus (MSSA), 50 Rif methicillin-resistant
Staphylococcus aureus (MRSA), and 50 rifampicin-resistant (Rif') MRSA.
Concerning RiF MRSA, the genetie alterations in the rpoB gene were
determined by PCR amplification and sequencing.
Results: The MICs of rifampicin and KRM-I648 for 90% ofRif Staphy-
lococ",s aureus isolates tested were 0.016 and 0.001 1Jg/ml, respectively.
Missense mutations within a 204 bp fragment covering clusters I and II of
the rifampicin resistance region could be demonstrated in all Rif" MRSA
isolates. The in vitro susceptibility testing of rifampicin and KRM-I648
against RiF MRSA isolates revealed different activities of the rifamycins
with respeL't to specific mutations within rpoB. Specific mutation sites could
be identified which exhibited high-level cross-resistance to both rifamycins.
while a subset of mutations were associated with an up to 100 fold better
activity ofKRM-l648.
Conclusions: The results provide evidence that the new rifamycin KRM-
1648 is a potent antimicrobial that displays a high activity even against a
subset of rifampicin-resistant Staphylococcus aureus isolates.
IWeP139[ Rapid detection of rifampidn resistance in
Mycobacterium tuberculosis clinical isolates using
mycobacteriophages
N. Galii,]. A. Dominguez, S. Blanco,]. lonca,]. M. Manterola, V.
Ausina
Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol,
BaJalona, Spain
Objectives: To standardise a rapid, non-laborious and low-cost assay to
srudy the susceptibility of M. tulm-CIIlosis (MTB) clinieal ioolates to rif.lmpi-
cin by using myeobaeteriophage 029.
